Advik Laboratories share price
BSE: 531686Pharmaceuticals & BiotechnologySmall Cap
Advik Laboratories Ltd. · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 1996
Last close ₹2.08₹0.00 (0.00%)
Share price at the BSE close on 26 Oct 2026. Previous close ₹2.08.
26 Oct: open ₹2.08, high ₹2.08, low ₹2.08
52-week range of traded prices to 26 Oct 2026
₹1.57Low, 2 Mar 2026₹2.08High, 15 Sep 2026
- Under BSE's graded surveillance, stage IV, on the list for 26 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹3.98 Cr5,167th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 58.03
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −180.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −14.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 109.84
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,364
Results
Standalone; ₹ crore.Advik Laboratories quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. Under it, revenue in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹0.00 CrQuarter to Mar 2026: ₹0.00 Cr
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹0.24 CrQuarter to Mar 2026: −₹0.36 Cr
Revenue by quarter
Peak revenue ₹0.00 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in 8 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | −0.22 | −0.17 | −0.28 | −0.22 | −0.22 | −0.22 | −0.36 | −0.24 |
Standalone. The last eight quarters. The latest is shaded.
Year to Mar 2026, against the year before
- RevenueRevenue. Under it, revenue in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- ₹0.00 CrYear to Mar 2025: ₹0.00 Cr
- Net profitNet profit. Under it, net profit in the year before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹1.02 CrYear to Mar 2025: −₹0.90 Cr
Revenue by year
Peak revenue ₹4.09 Cr, year to Mar 2018; lowest ₹0.00 Cr, year to Mar 2020
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 10 of the 10 years shown
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.27 | 4.09 | 0.82 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | −7.37 | −0.87 | −1.25 | −1.17 | −4.42 | −0.14 | −1.05 | −0.83 | −0.90 | −1.02 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary | −324.9% | −21.2% | −151.1% | – | – | −437.0% | – | – | – | – |
Standalone. Years to March. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICAL FORMULATIONS, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −48.1% | – | – | 0.0% |
| 3 years | −7.7% | – | – | 0.0% |
| 5 years | +17.1% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Advik Laboratories competitors and peers
Pharmaceuticals, 216 listed companies, priced on 27 Oct 2026. The table lists the 7 companies closest to Advik Laboratories in market cap. Advik Laboratories' own figures are from its last trade, on 26 Oct 2026. 2 companies in the table last traded before then: their rows are priced on their last trade.Healthcare companies
Advik Laboratories is not on the chart: it has no P/E today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Unjha FormulationsUNJHAFOR | 12 | 24.71 | 3.03 | +13.0% | +386.7% | 13.5% | 15.2% | 0.00% |
 Ortin GlobalORTINGLOBE | 10 | – | 8.38 | −58.3% | – | −56.2% | −52.2% | 0.00% |
 Dipna PharmachemDPL | 10 | – | – | – | – | – | – | 0.00% |
 Brawn BiotechBRAWN | 8 | 8.87 | 1.76 | +13.6% | – | 22.3% | −12.6% | 0.00% |
 Vivanza BiosciencesVIVANZA | 6 | 13.74 | 1.43 | +735.0% | – | 10.9% | 3.3% | 0.00% |
 Decipher LabsDECIPHER | 5 | – | 0.62 | −25.2% | – | – | −31.5% | 0.00% |
 Shyama Computronics and ServicesSHYAMACOMP | 4 | – | 0.36 | +9.4% | – | – | 0.6% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Advik Laboratories announcements
Oct 2026
10 Oct · Statement Of Investor Complaints For The Quarter Ended 30Thseptember, 2026
Advik Laboratories Submission of Annual Report for the Financial Year 2025-2026
Advik Laboratories share price by year
Each calendar year to 2025.Advik Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1.85 | −56.1% | 4.21 | 1.76 |
| 2024 | 4.21 | +50.9% | 4.29 | 2.79 |
| 2023 | 2.79 | +46.1% | 2.79 | 1.91 |
| 2022 | 1.91 | +50.4% | 1.91 | 1.27 |
| 2021 | 1.27 | +252.8% | 1.27 | 0.37 |
| 2020 | 0.36 | −2.7% | 0.37 | 0.32 |
| 2019 | 0.37 | −83.2% | 2.10 | 0.37 |
| 2018 | 2.20 | −59.5% | 7.03 | 2.11 |
| 2017 | 5.43 | −3.7% | 9.02 | 4.15 |
| 2016 | 5.64 | −52.7% | 14.32 | 4.68 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2021 is from its first session, 16 Feb 2021. The close is the year's last trade for 2022 (12 Dec 2022) and 2020 (11 Mar 2020).
Recent sessions
The 9 trading days to 19 Oct 2026, as traded on BSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 19 Oct 2026 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 | 300 |
| 12 Oct 2026 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 | 600 |
| 5 Oct 2026 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 | 2,200 |
| 28 Sep 2026 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 | 1,200 |
| 21 Sep 2026 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 | 400 |
| 15 Sep 2026 | 2.08 | 2.08 | 2.08 | 2.08 | 2.08 | 1,450 |
| 31 Aug 2026 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 201 |
| 17 Aug 2026 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 19,191 |
| 10 Aug 2026 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 6,100 |
Prices in ₹ per share as traded, not adjusted.
Company details
- BSE code
- 531686
- ISIN
- INE537C01019
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.advikindia.com
- CIN
- L74899HR1994PLC038300
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1994
- Registered office
- 138, Roz Ka Meo Industrial Area, Sohna, Distt Mewat, 122103, Haryana
- Share registrar
- MAS Services Ltd
- Keeps the register of shareholders and handles transfers and dividend payments